{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:33:24Z","timestamp":1792859604644,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["DFA\/BD\/6393\/2020"],"award-info":[{"award-number":["DFA\/BD\/6393\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04539\/2020: CIBB"],"award-info":[{"award-number":["UIDB\/04539\/2020: CIBB"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04539\/2020: CIBB"],"award-info":[{"award-number":["UIDB\/04539\/2020: CIBB"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, Portugal","award":["EXPL\/MEC-NEU\/0192\/2021"],"award-info":[{"award-number":["EXPL\/MEC-NEU\/0192\/2021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>LUMIPULSE G-automated immunoassays represent a widely used method for the quantification of Alzheimer\u2019s disease (AD) biomarkers in the cerebrospinal fluid (CSF). Less invasive blood-based markers confer a promising tool for AD diagnosis at prodromal stages (mild cognitive impairment (MCI)). Highly sensitive assays for the quantification of amyloid-beta (A\u03b2) and phosphorylated Tau-181 (p-Tau181) in the blood are showing promising results. In this study, we evaluated the clinical performance of the recently available fully automated LUMIPULSE plasma marker assays for detecting brain AD pathology and for predicting progression from MCI to AD dementia stage.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective exploratory cohort of 138 individuals (22 neurological controls [NC], 72 MCI, and 44 AD dementia patients) was included. Data regarding baseline CSF concentrations of A\u03b242, A\u03b240, t-Tau, and p-Tau181 was available and used to establish the presence of AD brain pathology. Baseline A\u03b242, A\u03b240, and p-Tau181 concentrations were determined in stored plasma samples using high-throughput fully automated LUMIPULSE assays. Progression from MCI to AD dementia was evaluated during follow-up (mean 6.4\u2009\u00b1\u20092.5\u00a0years). Moreover, a prospective validation cohort of 72 individuals with memory complaints underwent AD biomarker quantification, closely mirroring typical clinical practice. This cohort aimed to confirm the study\u2019s main findings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the exploratory cohort, correlations between CSF and plasma were moderate for p-Tau181 (<jats:italic>\u03c1<\/jats:italic>\u2009=\u20090.61, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and weak for A\u03b242\/A\u03b240 ratio (<jats:italic>\u03c1<\/jats:italic>\u2009=\u20090.39, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Plasma p-Tau181 and p-Tau181\/A\u03b242 concentrations were significantly increased while A\u03b242\/A\u03b240 was significantly decreased (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) in patients with AD dementia and prodromal AD, as well as in individuals with CSF abnormal amyloid concentrations (A\u2009+). Plasma p-Tau181 showed a robust performance in differentiating patients clinically diagnosed as AD (AUC\u2009=\u20090.89; 95% CI 0.83\u20130.94); A\u2009+\u2009vs. A\u2009\u2212\u2009(AUC\u2009=\u20090.84, 95% CI 0.77\u20130.91) and also in predicting conversion to AD dementia in MCI patients (AUC\u2009=\u20090.89, 95% CI 0.81\u20130.96). When tested in the validation cohort, plasma p-Tau181 displayed 83.3% of the overall percentage of agreement according to amyloid status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results show that the measurement of p-Tau181 in plasma has great potential as a non-invasive prognostic screening tool for implementation in a clinical setting.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-024-01397-9","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T07:02:34Z","timestamp":1709794954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer\u2019s disease pathology"],"prefix":"10.1186","volume":"16","author":[{"given":"Anuschka","family":"Silva-Sp\u00ednola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o","family":"Leit\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Le Bastard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Baldeiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"issue":"1","key":"1397_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14(1):32. https:\/\/doi.org\/10.1186\/s13024-019-0333-5.","journal-title":"Mol Neurodegener"},{"key":"1397_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzmn DM, Jaqust WJ, Petersen RC, Synder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1397_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, Contributors. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement."},{"issue":"2","key":"1397_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316. https:\/\/doi.org\/10.1016\/S1474-4422(12)70291-0.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1397_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13041-019-0448-1","volume":"12","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg H, Burnham SC. Blood-based molecular biomarkers for Alzheimer\u2019s disease. Mol Brain. 2019;12(1):26. https:\/\/doi.org\/10.1186\/s13041-019-0448-1.","journal-title":"Mol Brain"},{"issue":"1","key":"1397_CR6","doi-asserted-by":"publisher","first-page":"e14408","DOI":"10.15252\/emmm.202114408","volume":"14","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood-based biomarkers for Alzheimer\u2019s disease. EMBO Mol Med. 2022;14(1):e14408. https:\/\/doi.org\/10.15252\/emmm.202114408.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1397_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, van der Flier WM, Mielke MM, Del Campo M. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1397_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12375","volume":"14","author":"CJ Fowler","year":"2022","unstructured":"Fowler CJ, Stoops E, Rainey-Smith SR, Vanmechelen E, Vanbrabant J, Dewit N, Mauroo K, Maruff P, Rowe CC, Fripp J, Li QX, Bourgeat P, Collins SJ, Martins RN, Masters CL, Doecke JD. Plasma p-tau181\/A\u03b21-42 ratio predicts A\u03b2-PET status and correlates with CSF-p-tau181\/A\u03b21-42 and future cognitive decline. Alzheimers Dement (Amst). 2022;14(1): e12375. https:\/\/doi.org\/10.1002\/dad2.12375.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1397_CR9","doi-asserted-by":"publisher","unstructured":"Altomare D, Stampacchia S, Ribaldi F, Tomczyk S, Chevalier C, Poulain G, Asadi S, Bancila B, Marizzoni M, Martins M, Lathuiliere A, Scheffler M, Ashton NJ, Zetterberg H, Blennow K, Kern I, Frias M, Garibotto V, Frisoni GB. Plasma biomarkers for Alzheimer\u2019s disease: a field-test in a memory clinic. J Neurol Neurosurg Psychiatry. 2023:jnnp-2022\u2013330619. https:\/\/doi.org\/10.1136\/jnnp-2022-330619.","DOI":"10.1136\/jnnp-2022-330619"},{"issue":"2","key":"1397_CR10","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3390\/ijms24021226","volume":"24","author":"L Alvarez-Sanchez","year":"2023","unstructured":"Alvarez-Sanchez L, Pe\u00f1a-Bautista C, Ferre-Gonz\u00e1lez L, Balaguer A, Baquero M, Casanova-Estruch B, Ch\u00e1fer-Peric\u00e1s C. Assessment of plasma and cerebrospinal fluid biomarkers in different stages of Alzheimer\u2019s disease and frontotemporal dementia. Int J Mol Sci. 2023;24(2):1226. https:\/\/doi.org\/10.3390\/ijms24021226.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1397_CR11","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/acn3.51670","volume":"9","author":"AJ Aschenbrenner","year":"2022","unstructured":"Aschenbrenner AJ, Li Y, Henson RL, Volluz K, Hassenstab J, Verghese P, West T, Meyer MR, Kirmess KM, Fagan AM, Xiong C, Holtzman D, Morris JC, Bateman RJ, Schindler SE. Comparison of plasma and CSF biomarkers in predicting cognitive decline. Ann Clin Transl Neurol. 2022;9(11):1739\u201351. https:\/\/doi.org\/10.1002\/acn3.51670.","journal-title":"Ann Clin Transl Neurol"},{"key":"1397_CR12","doi-asserted-by":"publisher","first-page":"1126799","DOI":"10.3389\/fnagi.2023.1126799","volume":"15","author":"MY Chun","year":"2023","unstructured":"Chun MY, Jang H, Kim HJ, Kim JP, Gallacher J, Allu\u00e9 JA, Sarasa L, Castillo S, Pascual-Lucas M, Na DL, Seo SW, DPUK. Contribution of clinical information to the predictive performance of plasma \u03b2-amyloid levels for amyloid positron emission tomography positivity. Front Aging Neurosci. 2023;15:1126799. https:\/\/doi.org\/10.3389\/fnagi.2023.1126799.","journal-title":"Front Aging Neurosci."},{"issue":"4","key":"1397_CR13","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/alz.12801","volume":"19","author":"C Rabe","year":"2023","unstructured":"Rabe C, Bittner T, Jethwa A, Suridjan I, Manuilova E, Friesenhahn M, Stomrud E, Zetterberg H, Blennow K, Hansson O. Alzheimer\u2019s Disease Neuroimaging Initiative\u2020 and the Swedish BioFINDER study. Clinical performance and robustness evaluation of plasma amyloid-\u03b242\/40 prescreening. Alzheimers Dement. 2023;19(4):1393\u2013402. https:\/\/doi.org\/10.1002\/alz.12801.","journal-title":"Alzheimers Dement."},{"key":"1397_CR14","doi-asserted-by":"publisher","unstructured":"Ferreira P, Ferrari-Souza JP, Tissot C, Bellaver B, Leffa D, Lussier F, Povala G, Therriault J, Benedet AL, Ashton NJ, Cohen AD, Lopez OL, Tudorascu D, Klunk WE, Soucy JP, Gauthier S, Villemagne V, Zetterberg H, Blennow K, Rosa-Neto P, Zimmer ER, Karikari TK, Pascoal T; Alzheimer\u2019s Disease Neuroimaging Initiative. Potential utility of plasma P-Tau and neurofilament light chain as surrogate biomarkers for preventive clinical trials. Neurology. 2023. https:\/\/doi.org\/10.1212\/WNL.0000000000207115.","DOI":"10.1212\/WNL.0000000000207115"},{"key":"1397_CR15","doi-asserted-by":"publisher","unstructured":"Bilgel M, An Y, Walker KA, Moghekar AR, Ashton NJ, Kac PR, Karikari TK, Blennow K, Zetterberg H, Jedynak BM, Thambisetty M, Ferrucci L, Resnick SM. Longitudinal changes in Alzheimer\u2019s-related plasma biomarkers and brain amyloid. medRxiv [Preprint]. 2023:2023.01.12.23284439. https:\/\/doi.org\/10.1101\/2023.01.12.23284439.","DOI":"10.1101\/2023.01.12.23284439"},{"key":"1397_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15762","author":"A Silva-Sp\u00ednola","year":"2023","unstructured":"Silva-Sp\u00ednola A, Lima M, Leit\u00e3o MJ, Bernardes C, Dur\u00e3es J, Duro D, T\u00e1buas-Pereira M, Santana I, Baldeiras I. Blood biomarkers in mild cognitive impairment patients: relationship between analytes and progression to Alzheimer disease dementia. Eur J Neurol. 2023. https:\/\/doi.org\/10.1111\/ene.15762.","journal-title":"Eur J Neurol"},{"issue":"6","key":"1397_CR17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","volume":"93","author":"L Chouliaras","year":"2022","unstructured":"Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, Savulich G, Prats-Sedano MA, Heslegrave AJ, Zetterberg H, Su L, Rowe JB, O\u2019Brien JT. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2022;93(6):651\u20138. https:\/\/doi.org\/10.1136\/jnnp-2021-327788.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"1397_CR18","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, Karikari TK, Gonz\u00e1lez-Ortiz F, Di Molfetta G, Meda FJ, Jonaitis EM, Koscik RL, Cody K, Betthauser TJ, Li Y, Vanmechelen E, Palmqvist S, Stomrud E, Bateman RJ, Zetterberg H, Johnson SC, Blennow K, Hansson O. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28(12):2555\u201362. https:\/\/doi.org\/10.1038\/s41591-022-02074-w.","journal-title":"Nat Med"},{"issue":"2","key":"1397_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, Karikari TK, Lantero-Rodriguez J, Brum WS, Lussier FZ, Bezgin G, Stevenson J, Rahmouni N, Kunach P, Wang YT, Fernandez-Arias J, Socualaya KQ, Macedo AC, Ferrari-Souza JP, Ferreira PCL, Bellaver B, Leffa DT, Zimmer ER, Vitali P, Soucy JP, Triana-Baltzer G, Kolb HC, Pascoal TA, Saha-Chaudhuri P, Gauthier S, Zetterberg H, Blennow K, Rosa-Neto P. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 2023;80(2):188\u201399. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4485.","journal-title":"JAMA Neurol"},{"issue":"7","key":"1397_CR20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/medicina58070952","volume":"58","author":"J Cummings","year":"2022","unstructured":"Cummings J, Kinney J. Biomarkers for Alzheimer\u2019s disease: context of use, qualification, and roadmap for clinical implementation. Medicina (Kaunas). 2022;58(7):952. https:\/\/doi.org\/10.3390\/medicina58070952.","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"1397_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy S, Verberk IMW, den Dulk B, Hussainali Z, Zwan M, van der Flier WM, Ashton NJ, Zetterberg H, Blennow K, Vanbrabant J, Stoops E, Vanmechelen E, Dage JL, Teunissen CE. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res Ther. 2021;13(1):198. https:\/\/doi.org\/10.1186\/s13195-021-00939-9.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1397_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13195-022-01116-2","volume":"14","author":"EN Wilson","year":"2022","unstructured":"Wilson EN, Young CB, Ramos Benitez J, Swarovski MS, Feinstein I, Vandijck M, Le Guen Y, Kasireddy NM, Shahid M, Corso NK, Wang Q, Kennedy G, Trelle AN, Lind B, Channappa D, Belnap M, Ramirez V, Skylar-Scott I, Younes K, Yutsis MV, Le Bastard N, Quinn JF, van Dyck CH, Nairn A, Fredericks CA, Tian L, Kerchner GA, Montine TJ, Sha SJ, Davidzon G, Henderson VW, Longo FM, Greicius MD, Wagner AD, Wyss-Coray T, Poston KL, Mormino EC, Andreasson KI. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1):172. https:\/\/doi.org\/10.1186\/s13195-022-01116-2.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1397_CR23","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1515\/cclm-2022-0770","volume":"61","author":"G Musso","year":"2022","unstructured":"Musso G, Cosma C, Zaninotto M, Gabelli C, Basso D, Plebani M. Pre-analytical variability of the Lumipulse immunoassay for plasma biomarkers of Alzheimer\u2019s disease. Clin Chem Lab Med. 2022;61(3):e53\u20136. https:\/\/doi.org\/10.1515\/cclm-2022-0770.","journal-title":"Clin Chem Lab Med"},{"key":"1397_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s & Dement. 2011;7:263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimer\u2019s & Dement"},{"issue":"s1","key":"1397_CR25","doi-asserted-by":"publisher","first-page":"S647","DOI":"10.3233\/JAD-179908","volume":"64","author":"I Santana","year":"2018","unstructured":"Santana I, Baldeiras I, Santiago B, Duro D, Freitas S, Pereira MT, Almeida MR, Oliveira CR. Underlying biological processes in mild cognitive impairment: amyloidosis versus neurodegeneration. J Alzheimers Dis. 2018;64(s1):S647\u201357. https:\/\/doi.org\/10.3233\/JAD-179908.","journal-title":"J Alzheimers Dis"},{"key":"1397_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.43.2.250","volume":"43","author":"GC Roman","year":"1993","unstructured":"Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250\u201360.","journal-title":"Neurology."},{"key":"1397_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2217\/bmm.12.46","volume":"6","author":"M del Campo","year":"2012","unstructured":"del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, S\u00e1ez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M, Visser PJ, Teunissen C. Recommendations to standardize preanalytical confounding factors in Alzheimer\u2019s and Parkinson\u2019s disease cerebrospinal fluid biomarkers: an update. Biomark Med. 2012;6:419\u201330. https:\/\/doi.org\/10.2217\/bmm.12.46.","journal-title":"Biomark Med"},{"key":"1397_CR28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","volume":"7","author":"N Mattsson","year":"2011","unstructured":"Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Llad\u00f3 A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O\u2019Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schr\u00f6der J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tu-mani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K. The Alzheimer\u2019s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011;7:386\u201395. https:\/\/doi.org\/10.1016\/j.jalz.2011.05.2243.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1397_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13195-018-0362-2","volume":"10","author":"I Baldeiras","year":"2018","unstructured":"Baldeiras I, Santana I, Leit\u00e3o MJ, Gens H, Pascoal R, T\u00e1buas-Pereira M, Beato-Coelho J, Duro D, Almeida MR, Oliveira CR. Addition of the A\u03b242\/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer\u2019s disease dementia in mild cognitive impairment. Alzheimers Res Ther. 2018;10(1):33. https:\/\/doi.org\/10.1186\/s13195-018-0362-2.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1397_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13195-019-0550-8","volume":"11","author":"MJ Leit\u00e3o","year":"2019","unstructured":"Leit\u00e3o MJ, Silva-Sp\u00ednola A, Santana I, Olmedo V, Nadal A, Le Bastard N, Baldeiras I. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11(1):91. https:\/\/doi.org\/10.1186\/s13195-019-0550-8.","journal-title":"Alzheimers Res Ther"},{"key":"1397_CR31","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2023-0245","author":"A Mansilla","year":"2023","unstructured":"Mansilla A, Canyelles M, Ferrer R, Arranz J, Rodr\u00edguez-Baz \u00cd, Zhu N, Rubio-Guerra S, El Bounasri S, S\u00e1nchez O, Torres S, Fortea J, Lle\u00f3 A, Alcolea D, Tondo M. Effects of storage conditions on the stability of blood-based markers for the diagnosis of Alzheimer\u2019s disease. Clin Chem Lab Med. 2023. https:\/\/doi.org\/10.1515\/cclm-2023-0245.","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"1397_CR32","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/alz.12751","volume":"19","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist S, Stomrud E, Cullen N, Janelidze S, Manuilova E, Jethwa A, Bittner T, Eichenlaub U, Suridjan I, Kollmorgen G, Riepe M, von Arnim CAF, Tumani H, Hager K, Heidenreich F, Mattsson-Carlgren N, Zetterberg H, Blennow K, Hansson O. An accurate fully automated panel of plasma biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(4):1204\u201315. https:\/\/doi.org\/10.1002\/alz.12751.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1397_CR33","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette A, Janelidze S, Cullen N, Dage JL, Bateman RJ, Zetterberg H, Blennow K, Stomrud E, Mattsson-Carlgren N, Hansson O. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2023;19(4):1403\u201314. https:\/\/doi.org\/10.1002\/alz.12787.","journal-title":"Alzheimers Dement"},{"key":"1397_CR34","doi-asserted-by":"publisher","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E, Vanmechelen E, He Y, Dolado AO, Triana-Baltzer G, Pontecorvo MJ, Zetterberg H, Kolb H, Vandijck M, Blennow K, Bateman RJ, Hansson O. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2022:awac333. https:\/\/doi.org\/10.1093\/brain\/awac333.","DOI":"10.1093\/brain\/awac333"},{"issue":"1","key":"1397_CR35","doi-asserted-by":"publisher","first-page":"fcad024","DOI":"10.1093\/braincomms\/fcad024","volume":"5","author":"A den Braber","year":"2023","unstructured":"den Braber A, Verberk IMW, Tomassen J, den Dulk B, Stoops E, Dage JL, Collij LE, Barkhof F, Willemsen G, Nivard MG, van Berckel BNM, Scheltens P, Visser PJ, de Geus EJC, Teunissen CE. Plasma biomarkers predict amyloid pathology in cognitively normal monozygotic twins after 10 years. Brain Commun. 2023;5(1):fcad024. https:\/\/doi.org\/10.1093\/braincomms\/fcad024.","journal-title":"Brain Commun."},{"issue":"7","key":"1397_CR36","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD, Algeciras-Schimnich A, Knopman DS, Lowe VJ, Bu G, Vemuri P, Graff-Radford J, Jack CR Jr, Petersen RC. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022;28(7):1398\u2013405. https:\/\/doi.org\/10.1038\/s41591-022-01822-2.","journal-title":"Nat Med"},{"key":"1397_CR37","doi-asserted-by":"publisher","first-page":"e230199","DOI":"10.1001\/jamaneurol.2023.0199","volume":"29","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Barth\u00e9lemy NR, He Y, Bateman RJ, Hansson O. Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurol. 2023;29:e230199. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0199.","journal-title":"JAMA Neurol"},{"issue":"12","key":"1397_CR38","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, Salloway S, Sperling R, Zetterberg H, Teunissen CE. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2022;18(12):2669\u201386. https:\/\/doi.org\/10.1002\/alz.12756.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1397_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13024-023-00605-8","volume":"18","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK. Plasma phospho-tau in Alzheimer\u2019s disease: towards diagnostic and therapeutic trial applications. Mol Neurodegener. 2023;18(1):18. https:\/\/doi.org\/10.1186\/s13024-023-00605-8.","journal-title":"Mol Neurodegener"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01397-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01397-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01397-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T07:06:58Z","timestamp":1709795218000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01397-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1397"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01397-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"25 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and was approved by the Ethics Board of Coimbra University Hospital (OBS.SF.228\u20132021). Informed consent was obtained from all subjects involved in the study, or responsible caregivers, whichever was appropriate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.N. and N.LB. are employees of Fujirebio S.L. and N.V., respectively.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}